Breaking News, Collaborations & Alliances

Macomics, Ono Pharmaceutical Partner to Develop Immuno-oncology Antibody Drugs

Macomics will develop antibody candidates against a novel target using its ENIGMAC macrophage drug discovery platform.

Macomics Ltd., a drug discovery company, entered into a worldwide drug discovery collaboration agreement with Ono Pharmaceutical Co., to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Macomics will identify and characterize antibody candidates against the novel target of interest using its ENIGMAC macrophage drug discovery platform. Ono will have an exclusive option to license global rights to the candidates for further development and comm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters